Allosteric binding sites on muscarinic receptors

Drug Development Research

Volumn 40, Issue 2, 1997, Pages 193-204

  Ellis, John ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Alcuronium; Allosteric; Cooperativity; Gallamine; Muscarinic receptors

Indexed keywords

ACETYLCHOLINE; ALCURONIUM; GALLAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROMUSCULAR BLOCKING AGENT; OBIDOXIME; RECEPTOR SUBTYPE; STRYCHNINE; TUBOCURARINE CHLORIDE;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; HUMAN; MODEL; NONHUMAN; RECEPTOR AFFINITY; REVIEW; THEORY;

EID: 0031009786     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199702)40:2<193::AID-DDR9>3.0.CO;2-G     Document Type: Review

References (74)

1. Barlow RB, Berry KJ, Glenton PA, Nilolaou NM, Soh KS (1976): A comparison of affinity constants for muscarine-sensitive acetylcholine receptors in guinea-pig atrial pacemaker cells at 29 degrees C and in ileum at 29 degrees C and 37 degrees C. Br J Pharmacol 58:613-620.
2. Beld AJ, Van den Hoven S, Wouterse AC, Zegers MAP (1975): Are muscarinic receptors in the central and peripheral nervous system different? Eur J Pharmacol 30:360-363.
3. Birdsall NJM, Farries T, Gharagozloo P, Kobayashi S, Kuonen D, Lazareno S, Popham A, Sugimoto M (1997): Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Life Sci 60:1047-1052.
4. Birdsall NJ, Hulme EC, Kromer W, Stockton JM (1987): A second drugbinding site on muscarinic receptors. Fed Proc 46:2525-2527.
5. Botero Cid MH, Holzgrabe U, Kostenis E, Mohr K, Trankle C (1994): Search for the pharmacophore of bispyridinium-type allosteric modulators of muscarinic receptors. J Med Chem 37:1439-1445.
6. Burstein ES, Spalding TA, Brauner-Osborne H, Brann MR (1995): Constitutive activation of muscarinic receptors by the G-protein Gq. FEBS Lett 363:261-263.
7. Burstein ES, Spalding TA, Brann MR (1996): Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains. Biochem Pharmacol 51:539-544.
8. Changeux J-P (1966): Responses of acetylcholinesterase from Torpedo mannorata to salts and curarising agents. Mol Pharmacol 2:369-392.
9. Choo LK, Mitchelson F, Vong YM (1985): The interaction of McN-A-343 with pirenzepine and other selective muscarine receptor antagonists at a prejunctional muscarine receptor. Naunyn-Schmiedebergs Arch Pharmacol 328:430-438.
10. Clark AL, Mitchelson F (1976): The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 58:323-331.
11. Cohen-Armon M, Kloog Y, Henis YI, Sokolovsky M (1985): Batrachotoxin changes the properties of the muscarinic receptor in rat brain and heart: Possible interactions between niuscarinic receptors and sodium channels. Proc Natl Acad Sci USA 82:3524-3527.
12. Curtis CA, Wheatley M, Bansal S, Birdsall NJ, Eveleigh P, Pedder EK, Poyner D, Hulme EC (1989): Propylbenzilylcholine mustard labels an acidic residue in transmembrane helix 3 of the muscarinic receptor. J Biol Chem 264:489-495.
13. Dunlap J, Brown JH (1983): Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium. Mol Pharmacol 24:15-22.
14. Ehlert FJ (1986): "Inverse agonists," cooperativity and drug action at benzodiazepine receptors. Trends Pharmacol Sci 7:28-32.
15. Ehlert FJ (1988a): Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-104.
16. Ehlert FJ (1988b): Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium. J Pharmacol Exp Ther 247:596-602.
17. Ehlert FJ, Roeske WR, Gee KW, Yamamura HI (1983): An allosteric model for benzodiazepine receptor function. Biochem Pharmacol 32:2375-2383.
18. Ellis J, Hoss W (1982): Competitive interaction of gallamine with multiple muscarinic receptors. Biochem Pharmacol 31:873-876.
19. Ellis J, Seidenberg M (1992): Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 42:638-641.
20. Ellis J, Huyler J, Brann MR (1991): Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 42:1927-1932.
21. Ellis J, Seidenberg M, Brann MR (1993): Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions. Mol Pharmacol 44:583-588.
22. Fraser CM, Wang CD, Robinson DA, Gocayne JD, Venter JC (1989): Site-directed mutagenesis of ml muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol Pharmacol 36:840-847.
23. Gerstin EH, Jr.. LuongT, Ehlert FJ (1992): Heparin, dextran and trypan blue allosterically modulate M2 muscarinic receptor binding properties and interfere with receptor-mediated inhibition of adenylate cyclase. J Pharmacol Exp Ther 263:910-917.
24. Gharagozloo P, Lazareno S, Miyauchi M, Popham A, Birdsall NJ (1997): Synthesis of novel pentacyclic carbazoles as niuscarinic allosteric agents. Life Sci 60:1169.
25. 3H]acetylcholine to m2 muscarinic receptors. Biochem Pharmacol 52:1767-1775.
26. Hammer R, Berrie CP, Birdsall NJ, Burgen AS, Hulme EC (1980): Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283:90-92.
27. Harel M, Schalk I, Ehret-Sabatier L, Bouet E Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL (1993): Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 90:9031-9035.
28. Henis YI, Kloog Y, Sokolovsky M (1989): Allosteric interactions of muscarinic receptors and their regulation by other membrane proteins. In Brown JH (ed): The Muscarinic Receptors. Humana Press, Clifton, NJ, pp 377-418.
29. Hirschberg BT, Schimerlik MI (1994): A kinetic model for oxotremorine M binding to recombinant porcine m2 muscarinic receptors expressed in Chinese hamster ovary cells. J Biol Chem 269:26127-26135.
30. Hu J, El-Fakahany EE (1993): Allosteric interaction of dynorphin and myelin basic protein with muscarinic receptors. Pharmacol 47:351-359.
31. Hu J, Wang SZ, Forray C, El-Fakahany EE (1992): Complex allosteric modulation of cardiac muscarinic receptors by protamine: Potential model for putative endogenous ligands. .Mol Pharmacol 42:311-321.
32. Huang RRC, DeHaven RN, Cheung AH, Diehl RE, Dixon RAF, Strader CD (1990): Identification of allosteric antagonists of receptor-guanine nucleotide-binding protein interactions. Mol Pharmacol 37:304-310.
33. Hulme EC, Birdsall NJ, Buckley NJ (1990): Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 30:633-673.
34. Inch TD, Brimblecomb RW (1974): Antiacetylcholine drugs: Chemistry, stereochemistry, and pharmacology. Int Rev Neurobiol 16:67-144.
35. Jacoby DB, Gleich GJ, Fryer AD (1993): Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 91:1314-1318.
36. Jakubik J, Tucek S (1994): Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium. J Neurochem 63:1932-1940.
37. Jakubik J, Bacakova L, El-Fakahany EE, Tucek S (1995): Constitutive activity of the M1-M4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett 377:275-279.
38. Jakubik J, Bacakova L, Lisa V, El-Fakahany EE, Tucek S (1996): Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci USA 93:8705-8709.
39. Jerusalinsky D, Harvey AL (1994): Toxins from mamba venoms: Small proteins with selectivities for different subtypes of muscarinic receptors. Trends Pharmacol Sci 15:424-430.
40. Jones SV, Levey AI, Weiner DM, Ellis J, Novotny E, Yu S-H, Dorje F, Wess J, Brann MR (1992): Muscarinic acetylcholine receptors. In Brann MR (ed): Molecular Biology of G-Protein-Coupled Receptors. Boston: Birkhauser, pp 170-197.
41. Kenakin T (1996): Receptor conformation induction versus selection - all part of the same energy landscape. Trends Pharmacol Sci 17:190-191.
42. Kenakin T, Boselli C (1989): Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: Resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea. J Pharmacol Exp Ther 250:944-952.
43. Kenakin TP (1992): Tissue response as a functional discriminator of receptor heterogeneity: Effects of mixed receptor populations on Schild regressions. Mol Pharmacol 41:699-707.
44. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, Lefkowitz RJ (1992): Constitutive activation of the alpha IB-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433.
45. Lazareno S, Birdsall NJ (1995): Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
46. Lazareno S, Farries T, Gharagozloo P, Kuonen D, Popham A, Birdsall NJ (1997): Allosteric actions of brucine analogs at muscarinic receptor subtypes. Life Sci 60:1169.
47. Lee NH, El-Fakahany EE (1991a): Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem Pharmacol 42:199-205.
48. Lee NH, El-Fakahany EE (1991b): Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes. J Pharmacol Exp Ther 256:468-479.
49. Lee NH, Hu J, El-Fakahany EE (1992): Modulation by certain conserved aspartate residues of the allosteric interaction of gallamine at the m1 muscarinic receptor. J Pharmacol Exp Ther 262:312-316.
50. Leff P (1995): The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
51. Leppik RA, Miller RC, Eck M, Paquet JL (1994): Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. Mol Pharmacol 45:983-990.
52. Matsui H, Lazareno S, Birdsall NJ (1995): Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 47:88-98.
53. Max SI, Liang JS, Potter LT (1993a): Purification and properties of mitoxin, a specific antagonist of m1 muscarinic receptors. J Neurosci 13:4293-4300.
54. Max SI, Liang JS, Potter LT (1993b): Stable allosteric binding of m1-toxin to m1 muscarinic receptors. Mol Pharmacol 44:1171-1175.
55. Musilkova J, Tucek S (1995): Positive allosteric action of alcuronium on solubilized cardiac muscarinic receptors. Neurochem Int 27:337-343.
56. Poyner DR, Birdsall NJ, Curtis C, Eveleigh P, Hulme EC, Pedder EK, Wheatley M (1989): Binding and hydrodynamic properties of muscarinic receptor subtypes solubilized in 3-(3-cholamidopropyl)dimethylammonio-2-hydroxy-1-propanesulfonate. Mol Pharmacol 36:420-429.
57. Proska J, Tucek S (1994): Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol Pharmacol 45:709-717.
58. Proska J, Tucek S (1995): Competition between positive and negative allosteric effectors on muscarinic receptors. Mol Pharmacol 48:696-702.
59. Proska J, Tucek S (1996): Positive allosteric action of eburnamonine on cardiac muscarinic acetylcholine receptors. Eur J Pharmacol 305:201-205.
60. Ren Q, Kurose H, Lefkowitz RJ, Cotecchia S (1993): Constitutively active mutants of the alpha 2-adrenergic receptor. J Biol Chem 268:16483-16487.
61. Samama P, Cotecchia S, Costa T, Lefkowitz RJ (1993): A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
62. Soejima M, Noma A (1984): Mode of regulation of the ACh-sensitive K-channel by the muscarinic receptor in rabbit atrial cells. Pflugers Arch - Eur J Physiol 400:424-431.
63. Spalding TA, Birdsall NJ, Curtis CA, Hulme EC (1994): Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors. J Biol Chem 269:4092-4097.
64. Spalding TA, Burstein ES, Brauner-Osborne H, Hill-Eubanks D, Brann MR (1995): Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 275:1274-1279.
65. Stockton JM, Birdsall NJ, Burgen AS, Hulme EC (1983): Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23:551-557.
66. Tomlinson G, Hnatowich MR (1988): Apparent competitive inhibition of radioligand binding to receptors: Experimental and theoretical considerations in the analysis of equilibrium binding data. J Receptor Res 8:809-830.
67. Tucek S, Proska J (1995): Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol Sci 16:205-212.
68. Tucek S, Musilkova J, Nedoma J, Proska J, Shelkovnikov S, Vorlicek J (1990): Positive cooperativity in the binding of alcnronium and N-methylscopolamine to muscarinic acetylcholine receptors. Mol Pharmacol 38:674-680.
69. Waelbroeck M, Robberecht P, De Neef P, Christophe J (1988): Effects of d-tubocurarine on rat cardiac muscarinic receptors: A comparison with gallamine. J Receptor Res 8:787-808.
70. Waelbroeck M (1994): Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors. Mol Pharmacol 46:685-692.
71. 1 receptors. Eur J Pharmacol 305:187-192.
72. Wess J, Gdula D, Brann MR (1992): Structural basis of the subtype selectivity of muscarinic antagonists: A study with chimeric m2/m5 muscarinic receptors. Mol Pharmacol 41:369-374.
73. i-protein in membranes of human platelets. Biochem J 249:857-863.
74. Wreggett KA, Wells JW (1995): Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J Biol Chem 270:22488-22499.